Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.74 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194748 | 0.87 | HPGD (0.97) | HPGDTSHRMAPTSMN1; SMN2USP2 | |
| SCHEMBL30630165 | 0.81 | HPGD (0.56) | HPGDTSHRMAPTSMN1; SMN2USP2 | |
| SCHEMBL24747198 | 0.81 | HPGD (0.56) | HPGDTSHRMAPTSMN1; SMN2USP2 | |
| SCHEMBL4784836 | 0.81 | HPGD (0.85) | HPGDTSHRMAPTSMN1; SMN2USP2 | |
| SCHEMBL30630172 | 0.77 | MEN1 (0.64) | HPGDTSHRSMN1; SMN2POLBMEN1 | |
| SCHEMBL24747200 | 0.77 | MEN1 (0.64) | HPGDTSHRSMN1; SMN2POLBMEN1 | |
| SCHEMBL24746180 | 0.77 | HPGD (0.51) | HPGDTSHRSMN1; SMN2USP2MEN1 | |
| SCHEMBL2365790 | 0.76 | LMNA (0.65) | HPGDTSHRMAPTSMN1; SMN2USP2 | |
| SCHEMBL2366147 | 0.75 | ABL1 (0.47) | HPGDTSHRMAPTSMN1; SMN2MEN1 | |
| SCHEMBL2109571 | 0.74 | KEAP1 (0.48) | HPGDTSHRMAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951660-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8389743-B2 | Histamine-3 receptor antagonists | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120220568-A1 | Histamine-3 Receptor Antagonists | PFIZER INC. | 2012-08-30 | — | — | US | disclosed |
| US-8158673-B2 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | PFIZER INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1951660-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080096955-A1 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | PFIZER INC | 2008-04-24 | — | — | US | disclosed |
| WO-2007049123-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096955-A1 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | HRH3, HRH4, HRH2 | HPGD 1073/4885TSHR 862/4885MAPT 196/4885 |
| US-20120220568-A1 | Histamine-3 Receptor Antagonists | HRH3, HRH4, HRH1 | HPGD 2324/4885TSHR 166/4885MAPT 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.